{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:33:25Z","timestamp":1790660005533,"version":"4.1.0"},"reference-count":19,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.3960\/jslrt.24080","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:18:50Z","timestamp":1743113930000},"page":"68-71","source":"Crossref","is-referenced-by-count":5,"title":["Utility of CSF IL-6 monitoring in managing ICANS associated with                    Epcoritamab treatment: a case report and literature review"],"prefix":"10.3960","volume":"65","author":[{"given":"Atsushi","family":"Takahata","sequence":"first","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Kanagawa,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Akita","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Kanagawa,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Kanagawa,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Bando","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Kanagawa,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Kanagawa,                            Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Engelberts                            PJ,                                Hiemstra                            IH, de                                Jong                            B                    <i>et al.<\/i> DuoBody-CD3xCD20 induces potent T-cell-mediated killing                    of malignant B cells in preclinical models and provides opportunities for                    subcutaneous dosing. EBioMedicine. 2020; 52:                    102625.","DOI":"10.1016\/j.ebiom.2019.102625"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Lee                            DW,                                Gardner                            R,                                Porter                            DL                    <i>et al.<\/i> Current concepts in the diagnosis and management of                    cytokine release syndrome. Blood. 2014; 124: 188-195.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Cosenza                            M,                                Sacchi                            S,                                Pozzi                            S. Cytokine                    Release Syndrome Associated with T-Cell-Based Therapies for Hematological                    Malignancies: Pathophysiology, Clinical Presentation, and Treatment. Int J Mol                    Sci. 2021; 22: 7652.","DOI":"10.3390\/ijms22147652"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Thieblemont                            C,                                Phillips                            T,                                Ghesquieres                            H                    <i>et al.<\/i> Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific                    T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose                    Expansion in a Phase I\/II Trial. J Clin Oncol. 2023; 41:                    2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lee                            DW,                                Santomasso                            BD,                                Locke                            FL                    <i>et al.<\/i> ASTCT Consensus Grading for Cytokine Release Syndrome                    and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow                    Transplant. 2019; 25: 625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Le                            RQ,                                Li                            L,                                Yuan                            W                    <i>et al.<\/i> FDA Approval Summary: Tocilizumab for Treatment of                    Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine                    Release Syndrome. Oncologist. 2018; 23: 943-947.","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Gust                            J,                                Finney                            OC,                                Li                            D                    <i>et al.<\/i> Glial injury in neurotoxicity after pediatric                    CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86:                    42-54.","DOI":"10.1002\/ana.25502"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Gust                            J,                                Hay                            KA,                                Hanafi                            L-A                    <i>et al.<\/i> Endothelial Activation and Blood-Brain Barrier                    Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.                    Cancer Discov. 2017; 7: 1404-1419.","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Gust                            J,                                Ponce                            R,                                Liles                            WC,                                Garden                            GA,                                Turtle                            CJ. Cytokines in                    CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020; 11:                        577027.","DOI":"10.3389\/fimmu.2020.577027"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Santomasso                            BD,                                Park                            JH,                                Salloum                            D                    <i>et al.<\/i> Clinical and biological correlates of neurotoxicity                    associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic                    leukemia. Cancer Discov. 2018; 8: 958-971.","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Hirohata                            S,                                Kikuchi                            H. Role of                    intrathecal production of IL-6 in the pathogenesis of chronic progressive                    neuro-Beh\u00e7et\u2019s disease. J Neurol Sci. 2024; 463:                        123145.","DOI":"10.1016\/j.jns.2024.123145"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hopkins                            SJ,                                McMahon                            CJ,                                Singh                            N                    <i>et al.<\/i> Cerebrospinal fluid and plasma cytokines after                    subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection.                    J Neuroinflammation. 2012; 9: 255.","DOI":"10.1186\/1742-2094-9-255"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Neelapu                            SS,                                Locke                            FL,                                Bartlett                            NL                    <i>et al.<\/i> Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory                    Large B-Cell Lymphoma. N Engl J Med. 2017; 377: 2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Cohen                            AD,                                Garfall                            AL,                                Stadtmauer                            EA                    <i>et al.<\/i> B cell maturation antigen-specific CAR T cells are                    clinically active in multiple myeloma. J Clin Invest. 2019; 129:                    2210-2221.","DOI":"10.1172\/JCI126397"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ji                            Q,                                Dong                            Y,                                Zhang                            Y                    <i>et al.<\/i> Earlier intrathecal dexamethasone effectively alleviate                    immune effector cell-associated neurotoxicity syndrome. Int Immunopharmacol.                    2024; 142: 113214.","DOI":"10.1016\/j.intimp.2024.113214"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Berger                            SC,                                Fehse                            B,                                Aky\u00fcz                            N                    <i>et al.<\/i> Molecular monitoring of T-cell kinetics and migration in                    severe neurotoxicity after real-world CD19-specific chimeric antigen receptor T                    cell therapy. Haematologica. 2023; 108: 444-456.","DOI":"10.3324\/haematol.2022.281110"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Jung                            S,                                Greiner                            J, von                                Harsdorf                            S                    <i>et al.<\/i> Fatal late-onset CAR T-cell-mediated encephalitis after                    axicabtagene-ciloleucel in a patient with large B-cell lymphoma. Blood Adv.                    2021; 5: 3789-3793.","DOI":"10.1182\/bloodadvances.2021004889"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Matsuzono                            Y,                                Narita                            M,                                Akutsu                            Y,                                Togashi                            T. Interleukin-6                    in cerebrospinal fluid of patients with central nervous system infections. Acta                    Paediatr. 1995; 84: 879-883.","DOI":"10.1111\/j.1651-2227.1995.tb13784.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Mathiesen                            T,                                Andersson                            B,                                Loftenius                            A, von                                Holst                            H. Increased                    interleukin-6 levels in cerebrospinal fluid following subarachnoid hemorrhage. J                    Neurosurg. 1993; 78: 562-567.","DOI":"10.3171\/jns.1993.78.4.0562"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24080\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:50:08Z","timestamp":1743223808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24080\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24080","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"24080"}}